Novel anti-inflammatory peptides for lung inflammation and beyond

NOVEL

patented peptides

VALIDATED

TLR4 target

HIGH

unmet medical need

EVO-003

EVO-003 is EVORA Biosciences’ lead asset. A novel, patent-protected peptide which exhibits strong anti-inflammatory potency alongside a very favorable profile for development as an immunomodulatory drug.

Selective anti-inflammatory effect
Stable
Non-toxic
Amenable to multiple formulation options

ARDS

ARDS stands for Acute Respiratory Distress Syndrome. The lungs become inflamed for various reasons (virus, infection, trauma,…) and the patient’s immune system turns against them. The initial symptoms are breathing difficulties which may require external mechanical breathing support.

4 in 10 patients who suffer from ARDS do not survive.
Patients suffering from ARDS represent 10% of all Intensive Care Units (ICU) admissions.
There is currently no treatment for ARDS.
TLR4 is a validated target for ARDS treatment, making EVO-003 a first-in-class approach to treat ARDS.
In vivo results support a strong positive recovery from ARDS symptoms thanks to EVO-003.

Management

Hadrien Lanvin, MSc
CEO

Anna Kostrzak, PhD
Head of R&D

Directors

Hadrien Lanvin, MSc
CEO EVORA

Bruno Toque, PhD
Ex-Founder, CEO Exonhit Therapeutics

Philippe Rousseau, MSc
CEO Xenothera

Rémi Gloeckler, PhD
Ex-VP Industrial Partnerships, Ex-VP Industrial Operations
Transgene

Partners Network

EVORA Biosciences is supported by

contact@evorabio.com